Our data therefore suggest that molecular retargeting of preexisting antibodies is a feasible method to activate the tumor microenvironment and to improve infiltration by tumor-directed CD8 T cells to facilitate effective therapy using checkpoint inhibitors. Here, CD8A is linked to neoplasm.